ClinicalTrials.gg
CompletedNCT04299659LC_EntryUpdated Jul 20, 2023

Comparison of Four Methods for Entering the Gap Position of Landolt Cs

An observational study in Quality Control and Validation Study, sponsored by Aalen University. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Aalen University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
24
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The aim of this study is to investigate and compare the validity of four different input methods for Landolt Cs, i.e. the proportion of correct gap positions in relation to the total number of performances. The four input methods are a numeric keypad, an eight-positions rocker switch, a remote control and voice feedback.

Read the detailed description

The measurement of visual acuity is the most frequent and one of the most important ophthalmological functional investigations. Therefore, it is particularly important to find a measuring procedure with as little input errors as possible.

The 8-position Landolt C (LC) is the internationally accepted, well-standardised optotype for the determination of visual acuity.

Usually, the subjects informs the examiner verbally about the perceived position of each LC. According to the current literature, about 20 to 30 % of the population suffers from a right/left weakness. Furthermore, language barriers are an additional considerable hurdle.

Therefore, it is important to find an input method for the LC gap positions with minimal entry mistakes. In oder to avoid the thresholding procedure and its inherent difficulties, highly supra-threshold (10 times above the previously determined individual central visual acuity threshold) 8-position LCs are presented.

The study compares four input methods for entering of the Landolt C gap positions: a modified numeric keypad, an 8-position rocker switch, a modified TV remote control and voice/verbal feedback.

Each subject will perform all four input methods, with 2 test runs of 16 Landolt C presentations, each. A forced-choice method will be applied, i.e. the test is not continued until the test person has responded ot each single presentation. Regardless of whether the entry was correct or incorrect, the next Landolt C is displayed.

The optotypes are presented using modified version of the Freiburg Visual Acuity and Contrast Test (FrACT), which allows to present the 8-position Landolt Cs in a standardized way on a video display unit (VDU).

The sequence of the input methods is randomized. This study is carried out in a "within-subject design", i.e. all test persons go through all test conditions and serve as their own controls.

02

Conditions studied

  • Quality Control
  • Validation Study

Keywords

  • psychophysics
  • visual acuity
  • response
  • response entry
  • validity
  • retest reliability
  • reproducibility
  • evaluation
  • optotype
  • Landolt C
03

In context

Lead sponsor

Aalen University is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy, young subjects recruited for the students and or co-workers of the Aalen University of Applied Sciences

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: ≥ 18 years
  • (Distance) visual acuity with best correction: ≥ 0.8
  • (Distant) ametropia: ≤+8.0 Diopters (spherical equivalent)
  • Anisometropia ≤ 3 dpt
  • Astigmatism ≤ 2.5 dpt

Exclusion criteria

Exclusion Criteria:

  • Prolonged reaction time caused by drugs (medications)/ drugs/alcohol
  • Movement disorders (of hands) such as Parkinson's disease
  • Indication of amblyopia (strabismus surgery, occlusion therapy etc.)
  • Eye movement disorders/double vision
  • Defective stereo vision (according to LANG [I] stereo test)
  • Presence of a relative afferent pupil defect ("swinging flashlight test)
  • Any hint of visual pathway lesion or other chronic or progressive eye disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
24 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testLandolt C entry method

    Four different methods for entering the Landolt C gap position are compared

06

What researchers measure

Primary outcomes

  1. validity

    Proportion of correct gap position entries in relation to the total number of LC presentations by the four different entry methods

    Time frame: Through study completion, an average of 3 months

Secondary outcomes

  1. retest reliability

    Comparison of the correct gap position entry between first and second test run by the four different entry methods

    Time frame: Through study completion, an average of 3 months

  2. Examination duration

    Comparison of the examination duration of the the four different entry methods and by the first and second run

    Time frame: Through study completion, an average of 3 months

  3. Subjects´ satisfaction

    Subjects´ evaluation (using a questionnaire) for the four different entry methods

    Time frame: Through study completion, an average of 3 months

07

Study locations

1 site
  • Ulrich SCHIEFER
    Aalen, Deutschland 73430, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Mar 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2020
First posted
Mar 9, 2020
StartActual
Jul 22, 2022
Primary completionActual
Mar 1, 2023
CompletionActual
Jun 30, 2023
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04299659
Lead sponsor
Aalen University
Responsible party
Sponsor
First posted
Mar 9, 2020
Start date
Jul 22, 2022
Primary completion
Mar 1, 2023
Completion
Jun 30, 2023
Last update
Jul 20, 2023

Study contacts

Ulrich Schiefer, M.D.
study chair · +49 7361 576-4605

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion